Gene therapy strategies based on modifying tumour cells using high efficiency adenoviral vectors have shown promise in the clinic. Recently the Coxsackie and adenovirus receptor (CAR) has been shown to mediate adenoviral entry into tumour cells, although previous studies also suggested a role for MHC class I heavy chain. Detailed evaluation of the expression of both CAR and MHC class I in prostate cancer cell lines would have important implications for therapeutic strategies. We have found that, unlike cell lines derived from other malignancies, in human and murine prostate cancer loss of CAR expression appears to be relatively infrequent and does not correlate with loss of MHC class I expression. These findings, together with the demonstration of appreciable levels of cellsurface expression of integrins, suggest that cancer vaccine strategies based on modifying whole prostate cancer cells should be feasible using the current generation of recombinant adenoviral vectors, without deleterious effects on either the virus vector or the target cell.
Introduction
Prostate cancer incidence, morbidity and mortality has increased significantly over the last three decades. For patients with hormone-refractory disease no therapy has been shown to increase survival. Novel approaches to treatment have included a number of gene therapy strategies. However, as with other approaches, the basic limitations to developing effective treatment include the paucity of human and animal cell lines and a limited number of xenograft and transgenic models that do not accurately reflect human disease. An accurate assessment of gene transfer to, and manipulation of, available cell lines is clearly important. 1 -4 Modified human adenoviruses (Ads) have been pivotal in the development of gene therapy strategies for the treatment of genetic disorders and malignancies, including prostate cancer. 5, 6 Their particular advantages include high efficiency gene transfer to a wide variety of cell types, which may be infected when quiescent or actively dividing. However, the precise reasons for reduced gene transfer efficiency in certain tumour cells or certain tissues such as ciliated airway epithelia are not completely clear. 7 The use of viral vectors also has a number of disadvantages, including host immune responses to viral proteins which limit their repeated administration. 8 Human adenoviruses enter cells by receptor-mediated endocytosis, initiated by the interaction of the fibre protein with a cell surface receptor. 9, 10 Virus adsorption occurs when viral fibre proteins, which project from each of the 12 vertices of the icosahedral capsid, bind to specific cell surface receptors on a target cell plasma membrane. 9 The fibrereceptor interaction is accompanied by another binding event in which the penton base (into which the fibre protein is embedded), via an exposed repeated RGD motif, interacts with a v b 3 and a v b 5 integrins on the cell surface, leading to the internalisation of the virus. 11 Two proteins were thought to be the receptor for the subgroup C adenoviruses, the coxsackie B and adenovirus receptor, CAR 12, 13 and MHC class I heavy chain. 14 The a 2 domain of the MHC class I heavy chain had been thought to participate in binding of Ad5 fibre to cells. However, other studies showed that MHC class I expression in human tumour cells and a Chinese hamster ovary cell line expressing HLA-A2 did not correlate with Ad5 fibre binding or virus uptake. 15 Sequence analysis of human and mouse CAR cDNAs indicated that they encode 46 kDa membrane proteins with two immunoglobulinlike extracellular domains. 12, 13 One of these domains, termed D1, was later shown to interact with the knob domain of the Ad12 fibre protein, 16 and the precise residues that formed protein -protein contacts were determined by X-ray crystallographic and mutational analysis. 17, 18 In addition to the extracellular domains, CAR cDNA encodes a 22 amino acid transmembrane domain and a 107 amino acid intracellular domain that has a putative tyrosine phosphorylation site. 12 Engineered expression of the CAR protein has been used to facilitate the entry of Ad5 into cells which are poorly or not normally susceptible to adenovirus infection, thus augmenting gene delivery. 19 -22 It is likely that CAR possesses functions in addition to that of the cell receptor for Ad5. The physiological function of CAR, however, is still unknown, although recent evidence has pointed to a role for CAR in cell -cell interaction during mouse brain development, 23 which would be consistent with its postulated cell adhesion function. CAR receptor expression varies in different tumour types and one report has suggested that CAR receptor down-regulation may be closely correlated with tumour progression. 24 The aim of this study was to assess the suitability of a number of human and murine prostate cancer cell lines for cellular gene therapy by evaluating their susceptibility to transduction using a recombinant Ad5 and determining their expression of surface CAR and integrin molecules.
Material and methods

Cell lines
The MatLyLu (MLL) subline of the Dunning rat prostate cancer model was obtained from ECACC. The PAIII rat prostate cell line was kindly provided by Dr Morris Pollard (Lobund Laboratory, Indiana, USA). Cell lines P4E6, ShMac-1, ShMac-4 and ShMac-5 were developed by the Yorkshire Cancer Research Cancer Unit at the University of York.
The LNCaP, DU145 and PC-3 human prostate cancer cell lines were obtained from ECACC. The Onycap-1 and Onycap-23 cloned human prostate cell lines were kindly provided by Onyvax Limited (St George's Hospital, UK). LoVo and SW620 colorectal cell lines; NIH3T3 fibroblast cell line: T3M4, a pancreatic cell line and 293 cells, an Ad5-transformed human embryonic kidney cell line, were obtained from ECACC.
Cell culture
MatLyLu and PAIII cells were cultured in DMEM (Sigma, UK), 10% heat-inactivated foetal calf serum (FCS), 2 mM glutamine, 100 mg/ml penicillin, 100 mg/ml streptomycin, in 5% CO 2 at 37 C. LNCaP and DU145 cells were cultured in RPMI (Sigma, UK), 10% heat-inactivated FCS, 2 mM glutamine, 100 mg/ml penicillin, 100 mg/ml streptomycin; in 5% CO 2 at 37 C. PC-3 cells were cultured in DMEM, 10% heat inactivated FCS, 2 mM glutamine, 100 mg/ml penicillin, 100 mg/ml streptomycin, in 5% CO 2 at 37 C. Onycap-1, Onycap-23, P4E6, ShMac-1, ShMac-4 and ShMac-5 cells were cultured in keratinocyte basal medium (KBM) with 2.5% heat inactivated FCS, in 5% CO 2 at 37 C. LoVo, SW620, T3M4 and 293 cells were cultured in DMEM, 10% heat-inactivated FCS, 2 mM glutamine, 100 mg/ml penicillin, 100 mg/ml streptomycin, in 5% CO 2 at 37 C. All tissue culture reagents were filter sterilized by passage through a 0.22 mm filter and stored in sterile containers. Cell cultures were routinely passaged with 0.05% trypsin/EDTA solution (Sigma, UK) when 70 -80% confluent.
Cell viability assays
A 5 mg/ml stock solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide, Sigma, UK) was made up in PBS. Cells (1610 3 ) were plated out in 96-well flat-bottomed microtitre plates with 100 ml of appropriate medium. Depending on the nature of the experiment being performed, the duration of incubation and constituents of the medium added were varied. MTT solution (10 ml of stock per 100 ml of medium) was added and incubated for a further 4 h. The medium was then removed and the formazan crystals were dissolved in 200 ml of DMSO. Optical density was then measured at 550 nm using a Dynex MRX II plate reader (Dynex Technologies).
Transduction of cells by recombinant adenoviruses
One day before transduction, 2610 5 cells were plated out in a 10 cm dish, such that the monolayer would be 60% confluent on the following day. On the day of transduction, the medium was removed from the dishes and replaced with serum-free medium containing the replication-deficient, recombinant adenovirus Ad5-CMV-GFP (Quantum, USA) at the required multiplicity of infection (moi). In order to assess the efficiency of adenovirusmediated cell transduction, cells were exposed to a range of moi: 0, 0.1, 1, 3, 10 and 100. After 4 h of exposure to the virus, the virus-containing medium was removed and replaced with normal growth medium. The level of GFP expression in the cell lines was assessed 24, 48 and 72 h following exposure to the virus. Cells were harvested in the routine manner by treatment with trypsin and then washed three times with PBS. Samples were analysed immediately on a FACScan flow cytometer (Becton Dickinson, Oxford, UK). In order to ensure that exposure to recombinant adenovirus at high MOI had not affected cell viability, 1610 3 cells were plated out in 96-well plates and exposed to Ad5-CMV-EGFP in the same range of moi. After 24 h of growth, virus dilutions were adsorbed to the cells for 4 h, as described above. The viability of the cells was then assessed after 24, 48 and 72 h using the MTT assay.
Immunolabelling and flow cytometry
Phenotypic analysis of the human tumour cells was performed by surface staining (for 30 min at 4 C) with the following fluorochrome-conjugated (FITC) monoclonal antibodies: W6/32 (Serotec, UK), which recognizes an antigenic determinant shared along the HLA-A, -B, -C, and P1F6 (Chemicon, UK), which recognizes a v b 5 integrin, plus the respective isotype matched controls. Assessment of surface CAR expression was made using an indirect labelling method with RmcB anti-CAR monoclonal antibody (kindly provided by R Finburg, Division of Infectious Diseases, Dana-Farber Cancer Institute, Boston, MA, USA) followed by FITC-conjugated goat anti-mouse immunoglobulins. For characterization of the rat prostate cancer cell lines, the FITC conjugated anti-class I nonpolymorphic determinant antibody OX-18 (Pharmingen, UK) was used with the corresponding isotype-matched control. For each sample 10000 gated cellular events were acquired on a Becton Dickinson FACScan using CellQuest TM software and analysed using EXPO-32 TM software (Beckman Coulter).
Results
Expression of a green fluorescent protein transgene following adenovirus-mediated transduction of prostate tumour cell lines Uptake of adenovirus particles and expression of a transgene was studied by measuring expression of an enhanced green fluorescent protein (GFP) gene, placed under the control of a CMV promoter in a recombinant adenovirus. All cell lines were transduced with the recombinant Ad5-CMV-GFP virus and GFP expression assayed using flow cytometry. In addition, comparisons with non-transduced cells and control cell lines (derived from tissues other than the prostate) were made. Differing levels of GFP expression were detected in the cell lines, the level of expression increasing in proportion to the moi, as expected (Table 1 ). There was no evidence of significant cell death due to adenovirus transduction, even at the highest moi of 1000 : 1 by MTT assay (results not shown). However, the PC-3, ShMac-1 and MLL cell lines showed low levels of GFP, suggesting a reduced efficiency of gene transfer. This could be due to a number of reasons, including impaired binding of virus at the plasma membrane. This was investigated further by assaying levels of surface CAR and integrin molecules.
Expression of cell surface CAR and integrin molecules in prostate tumour cell lines
Cell surface expression of CAR was studied by flow cytometry using a monoclonal antibody, RmcB, against human CAR (Table 2 ). 12 Expression of CAR was detected in all cell lines but was reduced in the PC-3 cell line. This finding explained the reduced uptake of GFP (45.85%) in the same cell line. However, in other cell lines that were poorly transduced by recombinant adenoviruses (MLL Table 1 and ShMac-1), surface CAR levels were similar to those cell lines that were efficiently transduced. DU145 and the two rat cell lines showing low levels of MHC class I expression exhibited normal levels of CAR. All human and rat cell lines were positive for a v b 5 integrin expression, although the DU145 line showed slightly lower levels of expression.
Expression of surface MHC class I molecules in prostate tumour cell lines
Tumour cells were screened for the expression of surface MHC class I molecules using the W6/32 monoclonal antibody that recognizes a monomorphic determinant on class I heavy chains associated with b 2 -microglobulin. Cell surface expression of MHC class I molecules on prostate tumour and control cell lines is shown in Table  2 and representative FACS data from four cell lines is shown in Figure 1 . Apart from DU145, all human cell lines expressed surface MHC class I molecules, although the LNCaP cell line showed slightly reduced percentage of positive cells. Both rat prostate tumour cell lines PAIII and MLL were deficient in MHC class I expression. The control cell lines LoVo, SW620 and T3M4 displayed levels of surface class I molecules similar to those previously published. 25, 26 No correlation between MHC class I and CAR expression was noted ( Table 2 ).
Discussion
Gene therapy has shown great promise as a novel approach to treatment for patients with a wide range of malignancies. Of the various strategies considered so far, the transfer of cytokine or suicide genes into tumour cells has shown most promise from the clinical perspective. However, a particular frustration of gene therapy has been the poor efficiency of gene transfer using non-viral approaches. There are many advantages in using recombinant adenoviruses for gene therapy, reflected by the length of experience of their use in pre-clinical research. These advantages include the ability to transfer large transgenes to target cells at any point during the cell cycle. In addition, adenovirus particles are structurally stable and have been well characterized. There are no gene rearrangements after extensive amplification and passage of viruses in human cells and viral DNA is replicated without chromosomal integration, thus avoiding potential genotoxicity that may be associated with retroviral vectors. Previous studies have shown that certain tumour types are relatively resistant to adenovirus-mediated gene transfer. 27 -29 Two primary receptors have been reported to be required for the binding of Ad5 to susceptible cells: CAR and MHC class I heavy chains. The requirement for an interaction between adenoviruses and MHC class I molecules would have significant consequences for their application in cancer therapy, since loss of MHC class I expression occurs frequently in malignant tumours. Recent studies suggest that the wide spectrum of CAR levels observed among certain tumour cell lines including loss of CAR expression are due to transcriptional regulation, with no evidence so far of large gene alteration or rearrangement in the CAR gene between CAR-positive and CAR-negative cells. 28 In this study, reduced CAR expression was observed in only one cell line (PC-3) which correlated with reduced expression of GFP after adenovirus-mediated gene transfer. CAR expression differed amongst the cell lines tested, but these variations did not correlate with MHC class I expression, which itself was diminished in one human cell line (DU145) and both rat cell lines (PAIII and MLL). Interestingly, two cell lines ShMac-1 (human) and MLL (murine), displayed low levels of adenovirus-mediated gene transfer but had appreciable levels of surface CAR and integrins. The reason for this block to transduction is unknown and deserves further investigation. All rat and human cell lines expressed integrins, in contrast to a recent study which showed complete loss of a v b 3 and a v b 5 in 2 of 15 cell lines and cultures evaluated. 27 
Conclusion
In conclusion, unlike cell lines derived from other malignancies, loss of CAR expression appears to be relatively infrequent in prostate cancer cell lines and does not correlate with loss of MHC class I expression. These findings, combined with the demonstration of appreciable levels of cell-surface expression of integrins, suggest that, in future, cancer vaccine strategies based on modifying whole prostate cancer cells should be feasible using the current generation of recombinant adenovirus vectors, without deleterious effects on either the virus vector or the target cell.
